Stoke Therapeutics shares have doubled since June on hopes its Dravet drug works. The Phase 3 readout in 2026 is the only catalyst that matters.
Alpha Score of 67 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
Stoke Therapeutics shares have more than doubled since June. Behind the rally: the Phase 3 readout for its Dravet syndrome drug STK-001. Analysts following the company call it the sole catalyst.
An antisense oligonucleotide, STK-001 boosts SCN1A protein production. Its target is Dravet syndrome, a severe genetic epilepsy. Top-line data from the pivotal study is due in the first half of 2026.
September interim biomarker data gave the stock its lift. Dose-dependent SCN1A transcript increases. The stock jumped 40% in a single session. Evidence the mechanism works in humans, investors said. The data was not a clinical efficacy endpoint.
No approved products. No other late-stage programs. A miss on the seizure-frequency endpoint would erase the gains, analysts said. Cash stood at $267 million at the end of the third quarter, funding operations into 2027.
A positive readout would make STK-001 the first disease-modifying therapy for Dravet, the company has said. Its competitors: symptom-management drugs from Zogenix and Jazz Pharmaceuticals. The U.S. and European patient population is roughly 15,000.
Stoke is exploring STK-001 in other SCN1A-related epilepsies. Those programs are preclinical. The entire valuation hinges on the Phase 3 data, analysts said.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.